Skip to main content
. Author manuscript; available in PMC: 2020 Sep 8.
Published in final edited form as: Lung Cancer. 2019 Sep 23;137:113–122. doi: 10.1016/j.lungcan.2019.09.017

Figure 1.

Figure 1.

Median PFS with first-line EGFR-TKI treatment in EGFR mutation-positive NSCLC and the proportion of patients who received subsequent systemic treatment [6-12,19,29,32,33,102,103,138-142]

*As a proportion of patients who discontinued EGFR-TKI at data cut-off; treatment presumed systemic when details not provided; however, some references are not clear in this respect. Note, due to the differences in trial designs and patient populations, cross-trial comparisons should be interpreted with caution.